CCM Investment Advisers LLC Decreases Holdings in Vertex Pharmaceuticals Incorporated $VRTX

CCM Investment Advisers LLC decreased its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 7.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 26,249 shares of the pharmaceutical company’s stock after selling 2,060 shares during the quarter. CCM Investment Advisers LLC’s holdings in Vertex Pharmaceuticals were worth $11,900,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Central Pacific Bank Trust Division lifted its stake in Vertex Pharmaceuticals by 0.5% in the 4th quarter. Central Pacific Bank Trust Division now owns 5,026 shares of the pharmaceutical company’s stock valued at $2,279,000 after buying an additional 24 shares in the last quarter. Hohimer Wealth Management LLC raised its holdings in shares of Vertex Pharmaceuticals by 1.2% during the second quarter. Hohimer Wealth Management LLC now owns 2,123 shares of the pharmaceutical company’s stock valued at $945,000 after acquiring an additional 26 shares during the last quarter. Legacy Wealth Asset Management LLC raised its holdings in shares of Vertex Pharmaceuticals by 1.8% during the third quarter. Legacy Wealth Asset Management LLC now owns 1,442 shares of the pharmaceutical company’s stock valued at $565,000 after acquiring an additional 26 shares during the last quarter. Quent Capital LLC lifted its position in shares of Vertex Pharmaceuticals by 5.5% in the third quarter. Quent Capital LLC now owns 501 shares of the pharmaceutical company’s stock valued at $196,000 after acquiring an additional 26 shares in the last quarter. Finally, Washington Trust Advisors Inc. lifted its position in shares of Vertex Pharmaceuticals by 8.0% in the third quarter. Washington Trust Advisors Inc. now owns 349 shares of the pharmaceutical company’s stock valued at $137,000 after acquiring an additional 26 shares in the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Key Headlines Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Truist raised its price target on Vertex to $525 (from $490) and kept a Buy rating after encouraging Week‑36 interim results from Vertex’s Phase 3 RAINIER study — a clear positive catalyst supporting higher upside expectations. Truist Raises Vertex (VRTX) Price Target Following Phase 3 Trial Results
• Positive Sentiment: Multiple bullish writeups and retail/investor attention argue VRTX remains a buy—analysts and commentators point to durable CFTR franchise cash flows, pipeline upside and the recent dip as a potential buying opportunity. Is Vertex Pharmaceuticals Incorporated (VRTX) A Good Stock To Buy Now?
• Neutral Sentiment: Zacks and market headlines note VRTX outperformed the broader market in the latest session and is drawing elevated attention from Zacks users — this likely amplified buying interest but is descriptive rather than a fresh fundamental shift. Vertex Pharmaceuticals (VRTX) Laps the Stock Market: Here’s Why
• Neutral Sentiment: Reports of large short‑interest changes are inconsistent/placeholder in recent feeds (reported zeros/NaN), so there’s no clear short‑squeeze signal — effectively neutral on near‑term price pressure.
• Negative Sentiment: Competition risk: Maze Therapeutics reported positive Phase II data for an APOL1‑mediated kidney disease drug that targets the same pathway Vertex is pursuing — the news highlights competitive risk to Vertex’s AMKD franchise, which could weigh on long‑term upside if competitors advance. Maze tumbles despite positive data for kidney disease drug

Insider Activity

In other Vertex Pharmaceuticals news, CMO Carmen Bozic sold 2,329 shares of the business’s stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $481.79, for a total value of $1,122,088.91. Following the sale, the chief marketing officer owned 35,405 shares of the company’s stock, valued at $17,057,774.95. The trade was a 6.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Charles F. Wagner, Jr. sold 9,532 shares of the company’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $461.00, for a total value of $4,394,252.00. Following the transaction, the executive vice president owned 37,725 shares in the company, valued at $17,391,225. This trade represents a 20.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 93,485 shares of company stock worth $43,967,586 in the last three months. 0.20% of the stock is currently owned by corporate insiders.

Vertex Pharmaceuticals Stock Up 1.4%

NASDAQ:VRTX opened at $454.97 on Thursday. The company has a market capitalization of $115.58 billion, a P/E ratio of 29.68, a P/E/G ratio of 1.92 and a beta of 0.31. Vertex Pharmaceuticals Incorporated has a 52 week low of $362.50 and a 52 week high of $510.77. The stock’s fifty day moving average is $468.97 and its two-hundred day moving average is $441.56.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 EPS for the quarter, missing analysts’ consensus estimates of $5.05 by ($0.02). Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. The company had revenue of $3.19 billion during the quarter, compared to analyst estimates of $3.18 billion. During the same period in the previous year, the company earned $3.98 EPS. The company’s quarterly revenue was up 9.5% compared to the same quarter last year. Sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

VRTX has been the subject of several research reports. Wells Fargo & Company boosted their price target on Vertex Pharmaceuticals from $460.00 to $515.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 10th. Jefferies Financial Group initiated coverage on Vertex Pharmaceuticals in a report on Tuesday, March 10th. They issued a “buy” rating and a $580.00 price objective on the stock. Truist Financial lifted their target price on shares of Vertex Pharmaceuticals from $490.00 to $525.00 and gave the stock a “buy” rating in a research note on Wednesday, March 11th. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $577.00 target price on shares of Vertex Pharmaceuticals in a report on Friday, February 13th. Finally, Weiss Ratings upgraded shares of Vertex Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, February 4th. Twenty-four analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $554.30.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.